EUVIMEDEUVIMED entdecken
Crossref

Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer

Conglei Zhou, Shuang Zhao, Yongbo Zhang, Jianjun Cheng iD, Jiahua Shi iD, Guanhua Du iD

Small · 2024

DOI: 10.1002/smll.202310565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2024. Verfasst von Conglei Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicine and Immune Engineering, Henan University, Kaifeng, Henan, 475004, China. Hauptthemen laut MEDLINE: Indoles, Polymers, Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Joint Fund of Science and Technology R&D Program of Henan Province, Key R&D and Promotion Projects in Henan Province, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy utilizing anti‐PD‐L1 blockade has achieved dramatic success in clinical breast cancer management but is often hampered by the limited immune response. Increasing evidence shows that immunogenic cell death (ICD) recently arises as a promising strategy for enlarging tumor immunogenicity and eliciting systemic anti‐tumor immunity effectively. However, developing simple but versatile, highly efficient but low‐toxic, biosafe, and clinically available transformed ICD inducers remains a huge demand and is highly desirable. Herein, a multifunctional ICD inducer is purposefully developed A6‐MPDA@PAL by integrating photothermal therapy (PTT) nanoplatforms mesoporous polydopamine (MPDA), CDK4/6 inhibitor palbociclib (PAL), and CD44‐specific targeting A6 peptide in a simple way for augmenting the immune antitumor efficacy of anti‐PD‐L1 therapy. Remarkably, the light‐inducible nanoplatforms exhibit multiple favorable therapeutic features ensuring a superior and biosafe PTT/chemotherapy efficacy. Together with stronger accumulative ICD induction, single administration of A6‐MPDA@PAL can trigger robust systemic antitumor immunity and abscopal effect with the assistance of anti‐PD‐L1 blockade by fascinating the intratumoral infiltration of T lymphocytes and reversing the immunosuppressive tumor microenvironment simultaneously, therapy achieving brilliant synergistic immunotherapy with effective tumor ablation. This study presents a simple and smart ICD inducer opening up attractive clinical possibilities for reinforcing the anti‐PD‐L1 therapy against breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesPolymersBreast NeoplasmsImmunotherapyCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4FemaleAnimalsMiceHumansCell Line, TumorPorosityPyridinesPiperazinesProtein Kinase InhibitorsPhotothermal Therapy

Stichwörter der Autor:innen

CDK4/6 inhibitorimmunogenic cell deathmesoporous polydopaminephotothermal therapysynergistic immunotherapy

Substanzen

polydopamineIndolesPolymersCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4PyridinespalbociclibPiperazinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Natural Medicine and Immune Engineering, Henan University, Kaifeng, Henan, 475004, China.
  • State Key Laboratory of Antiviral Drugs, Henan University, China.
  • Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.

ORCID-Profile: Jianjun Cheng, Jiahua Shi, Guanhua Du

Förderung

  • Joint Fund of Science and Technology R&D Program of Henan Province
  • Key R&D and Promotion Projects in Henan Province
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Henan Province
  • Key Scientific Research Program of the Higher Education Institutions of Henan Province

Zitieren

APA

Zhou, C., Zhao, S., Zhang, Y., Cheng, J., Shi, J., & Du, G. (2024). Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer. Small. https://doi.org/10.1002/smll.202310565

Vancouver

Zhou C, Zhao S, Zhang Y, Cheng J, Shi J, Du G. Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer. Small. 2024. doi:10.1002/smll.202310565

BibTeX
@article{Zhou2024,
  author = {Zhou, Conglei and Zhao, Shuang and Zhang, Yongbo and Cheng, Jianjun and Shi, Jiahua and Du, Guanhua},
  title = {Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202310565}
}
Kostenlos starten →